What Can You Expect in 2026?
The 10th MASH Drug Development Summit is the industry's definitive forum dedicated exclusively to advancing efficacious MASH therapeutics from discovery through clinical development.
As the field enters a new era following the approvals of Madrigal Pharmaceuticals' Rezdiffra and Novo Nordisk's Wegovy, MASH has evolved from a long-standing scientific challenge into a commercially validated therapeutic category. At the same time, growing investment in FGF-21 analogs, combination therapies, non-invasive biomarkers and AI-enabled pathology tools is transforming how therapies are discovered, developed and evaluated.
This summit is your opportunity to understand how leading pharmaceutical and biotechnology companies are responding to this rapidly evolving landscape. Across three days, senior discovery, translational, clinical and regulatory leaders will share strategies to improve patient stratification, strengthen translational confidence, validate non-invasive endpoints and develop differentiated therapies capable of delivering meaningful fibrosis improvement and long-term patient benefit.
Join industry leaders from Novo Nordisk, Madrigal Pharmaceuticals, Pfizer, AstraZeneca, Takeda Pharmaceuticals, Akero Therapeutics, Rivus Pharmaceuticals, Insitro, Cellarity and Harvard Medical School to benchmark development strategies, exchange lessons learned and forge the collaborations shaping the future of MASH drug development.
Unmissable Event Highlights
Advance Translational Confidence Through Human-Relevant Models
Evaluate the latest in vitro, in vivo and ex vivo systems alongside AI-enabled discovery approaches to improve target validation, reduce translational risk and increase the likelihood of clinical success, with Insitro, Viscient Biosciences, Engitix, Genentech & GlaxoSmithKline
Navigate the Transition to a Post-Approval MASH Landscape
Explore how active comparators, evolving standards of care and non-invasive endpoints are reshaping clinical development and registrational strategy, with Madrigal Pharmaceuticals, Novo Nordisk, AstraZeneca & Pfizer
Unlock the Potential of Next-Generation Therapeutic Strategies
Assess emerging combination approaches, differentiated anti-fibrotic mechanisms and precision medicine strategies designed to address disease heterogeneity and improve long-term outcomes, with Akero Therapeutics, AstraZeneca, Rivus Pharmaceuticals & Cellarity
Learn Directly from the Leaders Defining the Future of MASH
Hear first-hand perspectives from 70+ senior discovery, translational, clinical and regulatory leaders spanning pharmaceutical companies, biotechnology innovators and academic institutions committed to advancing efficacious MASH therapies
Get access to:
- Get the full agenda at a glance – covering session details and focus day content
- See the complete 25+ speaker faculty - from Takeda, Pfizer, AstraZeneca & more
- Understand the key scientific themes - covering discovery through to clinical development
- Preview who you’ll meet – attendee profiles, company types and networking formats
- Explore partnership and registration options – including pricing, deadlines, discounts and opportunities to showcase solutions
Attending Companies Include
Explore the Agenda
Reflect on the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Industry Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.